Clik here to view.
Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
Filed under: Investing Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when...
View ArticleClik here to view.
How Microsoft Can Make Skype a Competing Mobile Messaging Platform
Filed under: Investing In 2011, Microsoft paid $8.5 billion to eBay and private-equity and venture-capital investors to acquire Skype, an Internet-based calling and messaging service. Despite now being...
View ArticleClik here to view.
Jack Bogle: "Liquidity Is the Last Refuge of the Scoundrel"
Filed under: Investing John C. Bogle is the founder and retired CEO of The Vanguard Group, the largest mutual-fund organization in the world, with more than 160 mutual funds and current assets totaling...
View ArticleClik here to view.
Bristol-Myers Squibb: More Than Just a Relief Rally?
Filed under: Investing Last week was strong for shares in Bristol-Myers Squibb , which rallied 3% while the S&P 500 was up less than 1%. Here's why that is and also why Bristol-Myers Squibb may...
View ArticleClik here to view.
Ford's Mark Fields on Ford's Big Plans for China
Filed under: Investing The Motley Fool recently had a chance to spend some time talking with Ford's Mark Fields -- and we got it all on video to share with you. Fields' name may not yet be a familiar...
View ArticleClik here to view.
Can Gilead Dominate The HIV Drug Market Again in 2014?
Filed under: Investing Gilead's slate of HIV drug therapies helped it capture the bulk of the market in 2013, outpacing competing therapies from Johnson & Johnson and Bristol-Myers . Sales from...
View ArticleClik here to view.
Are You There, GM? It's Me, the Federal Government
Filed under: Investing Last month, General Motors recalled 1.6 million cars over a problem with ignition switches that suddenly turned off and cut power. Now federal prosecutors are investigating...
View ArticleClik here to view.
Super Painkiller May Be in Trouble
Filed under: Investing Shares of Zogenix took an awful 20% haircut today, on news emerging from a potential competitor. Zogenix's new super painkiller, Zohydro, is extremely potent and effective,...
View ArticleClik here to view.
Will "Peabody" Disappoint DreamWorks' Investors?
Filed under: Investing DreamWorks Animation investors can breathe a sigh of relief: The company's Mr. Peabody & Sherman film is off to a solid start in theaters. The movie grossed $32.5 million in...
View ArticleClik here to view.
The 3 Most Thought-Provoking Industrial Articles: February 2014
Filed under: Investing Each month, the writers and staff at The Motley Fool vote for the highest-quality industrial articles out of the hundreds published each month. Here are the winners for February....
View ArticleClik here to view.
2 Small Apple Inc. Business Segments About to Get Bigger
Filed under: Investing Most of the financial coverage surrounding Apple stock is focused on the company's iPhone, iPad, and Mac businesses. But two of its smaller businesses are about to get much...
View ArticleClik here to view.
David Gardner Shares 3 Keys to Picking a Great Stock
Filed under: Investing Co-founders Tom and David Gardner look back on The Motley Fool's journey with Amazon.com since first purchasing it in September 1997. The brothers discuss the ups and downs...
View ArticleClik here to view.
Do the Shorts Have the Upper Hand in Herbalife?
Filed under: Investing Herbalife continues to be a battleground between investors and short-sellers, made more prominent by big-name hedge-fund managers Carl Icahn and Bill Ackman taking aggressive...
View ArticleClik here to view.
The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
Filed under: Investing Not every company in biotech land is loved by investors. In fact, many biotechs top the list of companies with high short interest as a percentage of float. As of the end of...
View ArticleClik here to view.
3 Reasons Pfizer, Inc. Can Overcome Celebrex Patent Loss
Filed under: Investing Pfizer lost its court battle yesterday to extend the patent life of its blockbuster painkiller, Celebrex, through 2015. Reportedly, there are five companies clamoring to sell...
View ArticleClik here to view.
Target's $100 Million Bet: Will It Pay Off?
Filed under: Investing Target.com Target suffered a significant blow with the data breach. Not only will it now have to contend with a myriad of expenses, but some of its customers lost trust in the...
View ArticleClik here to view.
3 Health Care Companies Warren Buffett Loves
Filed under: Investing Warren Buffett believes in buying companies for the long haul, so Berkshire Hathaway's positions are usually concentrated bets on businesses that are easy to understand. While...
View ArticleClik here to view.
BMW Profits Gain on Strong Sales Growth
Filed under: Investing The stunning i8 hybrid sports car is just one of several all-new BMWs due this year. Photo credit: BMW. German luxury-car giant BMW reported a surprise fourth-quarter-profit gain...
View ArticleClik here to view.
Ford's Mark Fields: We're Bullish on India
Filed under: Investing The Motley Fool recently had a chance to spend some time talking with Ford's Mark Fields -- and we got it all on video to share with you. Fields' name may not yet be a familiar...
View ArticleClik here to view.
Jack Bogle Considers the Future of Vanguard
Filed under: Investing John C. Bogle is the founder and retired CEO of The Vanguard Group, the largest mutual-fund organization in the world, with more than 160 mutual funds and current assets totaling...
View Article